Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Mersana has continued to advance the dose escalation ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...

Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously tr ...

Mersana has continued to advance the dose escalation portion ... to reduced costs associated with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses ...